Genelabs Technologies Inc. has laid the groundwork for a confirmatory Phase III trial of its lupus drug, Prestara, and said it expects to begin the trial before the end of the year. (BioWorld Today)
Genelabs Technologies Inc. has laid the groundwork for a confirmatory Phase III trial of its lupus drug, Prestara, and said it expects to begin the trial before the end of the year. (BioWorld Today)
Celgene Corp. is shelling out $45 million in stock and options to acquire a subsidiary - a placental stem cell recovery company called Anthrogenesis Corp. (BioWorld Today)
Celgene Corp. is shelling out $45 million in stock and options to acquire a subsidiary - a placental stem cell recovery company called Anthrogenesis Corp. (BioWorld Today)
Ligand Pharmaceuticals Inc. is restructuring its Avinza license deal with Elan Corp. plc, eliminating Elan's co-promotion rights in North America and dropping Elan's royalty rate. But to do so, Ligand will pick up $135 million in debt for a product that is not generating revenue as strongly as management had predicted, a scenario that has investors questioning the future.
Ligand Pharmaceuticals Inc. is restructuring its Avinza license deal with Elan Corp. plc, eliminating Elan's co-promotion rights in North America and dropping Elan's royalty rate. But to do so, Ligand will pick up $135 million in debt for a product that is not generating revenue as strongly as management had predicted, a scenario that has investors questioning the future.
Incyte Genomics Inc., known for its databases and research solutions, is acquiring Maxia Pharmaceuticals Inc. and its pipeline of early stage drugs for an amount that could reach $42.3 million. Also Tuesday, the company released its third-quarter earnings and said it was reducing staff by 37 percent and planning to seriously reduce expenses. (BioWorld Today)
Incyte Genomics Inc., known for its databases and research solutions, is acquiring Maxia Pharmaceuticals Inc. and its pipeline of early stage drugs for an amount that could reach $42.3 million. Also Tuesday, the company released its third-quarter earnings and said it was reducing staff by 37 percent and planning to seriously reduce expenses. (BioWorld Today)
